TQB0 Stock Chart & Stats
€1.12
-€0.07(-5.88%)
At close: 4:00 PM EDT
€1.12
-€0.07(-5.88%)
Day’s Range― - ―
52-Week Range€0.84 - €2.80
Previous CloseN/A
Volume0.00
Average Volume (3M)50.00
Market Cap
€47.35M
Enterprise Value€57.43
Total Cash (Recent Filing)€7.63M
Total Debt (Recent Filing)€3.49M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Dec 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding46,987,297
10 Day Avg. Volume0
30 Day Avg. Volume50
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)6.39
Price to Sales (P/S)4.89
P/FCF Ratio-5.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.78Price Target Upside237.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.27
Revenue Forecast (FY)€17.56M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue GrowthFive consecutive quarters of year-over-year growth indicate improving commercial traction and customer adoption across MindWalk’s platforms. Continued expansion provides a stronger foundation for operating leverage and supports the strategic transition toward recurring, platform-based revenue over the next several quarters.
Pharmaceutical Customer And Clinical ValidationDeep relationships with leading pharmaceutical companies and a track record of molecules reaching clinical trials support MindWalk’s credibility in a regulated, specialized market. This validation can improve access to enterprise opportunities and create durable demand for its biological AI infrastructure.
Proprietary Biological AI InfrastructureThe HYFT-based context layer is designed to organize reusable biological information across programs and models, while the patent filing seeks additional protection for its data architecture. This supports differentiation and may allow the platform to compound value across recurring customer workflows.
Bears Say
Persistent Operating And Net LossesSevere operating and net losses show that MindWalk has not yet reached a sustainable earnings model despite improved gross margins. Continued losses require substantial scale or cost reductions to achieve breakeven, leaving profitability dependent on successful commercialization and disciplined expense management.
Cash Burn And Equity ErosionPersistent negative operating and free cash flow means reported losses are translating into substantial cash outflows, reducing financial flexibility. The sharp decline in equity further weakens the capital base, increasing dependence on financing or faster revenue conversion to sustain operations.
Uncertain ReefIQ MonetizationReefIQ’s strategic potential is not yet matched by contracted revenue visibility. Milestone-based launches, security and governance reviews, and lengthy procurement processes can delay conversion, making near-term revenue difficult to forecast and complicating planning for investment and cash needs.
MindWalk Holdings News
TQB0 FAQ
What was MindWalk Holdings’s price range in the past 12 months?
MindWalk Holdings lowest stock price was €0.84 and its highest was €2.80 in the past 12 months.
What is MindWalk Holdings’s market cap?
MindWalk Holdings’s market cap is €47.35M.
When is MindWalk Holdings’s upcoming earnings report date?
MindWalk Holdings’s upcoming earnings report date is Dec 10, 2026 which is in 83 days.
How were MindWalk Holdings’s earnings last quarter?
MindWalk Holdings released its earnings results on Sep 14, 2026. The company reported -€0.081 earnings per share for the quarter, missing the consensus estimate of -€0.048 by -€0.033.
Is MindWalk Holdings overvalued?
According to Wall Street analysts MindWalk Holdings’s price is currently Undervalued.
Does MindWalk Holdings pay dividends?
MindWalk Holdings does not currently pay dividends.
What is MindWalk Holdings’s EPS estimate?
MindWalk Holdings’s EPS estimate is -0.05.
How many shares outstanding does MindWalk Holdings have?
MindWalk Holdings has 46,987,297 shares outstanding.
What happened to MindWalk Holdings’s price movement after its last earnings report?
MindWalk Holdings reported an EPS of -€0.081 in its last earnings report, missing expectations of -€0.048. Following the earnings report the stock price went down -14.091%.
Which hedge fund is a major shareholder of MindWalk Holdings?
Currently, no hedge funds are holding shares in DE:TQB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MindWalk Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.78 (237.60% Upside)
€3.78 (237.60% Upside)
Blogger Sentiment
Neutral
DE:TQB0 Sentiment 50%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-58.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MindWalk Holdings
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
TQB0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive, supported by 21% year-over-year revenue growth, five consecutive quarters of year-over-year growth, gross margin expansion to 59%, progress launching ReefIQ, a strong pharmaceutical customer base, clinical validation, platform partnership traction, and a USD 30 million non-dilutive financing commitment. The main negative factors were the increased $6.1 million loss, higher operating expenses, a lower cash balance, uncertain and potentially lumpy timing for ReefIQ revenue, and the absence of announced enterprise contracts or specific closing timelines.View all DE:TQB0 earnings summariesTQB0 Stock 12 Month Forecast
Average Price Target
€3.78
▲(237.60% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―